Your SlideShare is downloading. ×
New Report Analyzes the Potential of Therapeutic Monoclonal Antibodies in India
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

New Report Analyzes the Potential of Therapeutic Monoclonal Antibodies in India

104

Published on

Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: …

Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016”.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
104
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. New Report Analyzes the Potential of Therapeutic MonoclonalAntibodies in IndiaResearch firm IMARC Group expects this market to grow at a CAGR of around 26% during2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report &Forecast: 2012-2016”.A huge patient pool, increasing prevalence of health insurance, strong biosimilar manufacturingcapabilities and a largely unpenetrated market are expected to be the catalysts in driving themarket for monoclonal antibodies in India. Research firm IMARC Group expects this market togrow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “IndianMonoclonal Antibodies Market Report & Forecast: 2012-2016”.According to an analyst at IMARC Group, “India’s poor historical track record in Intellectualproperty protection has resulted in many Indian companies acquiring strong reverse engineeringskills. The Indian generic industry provides generic drugs not only to India but to the entireworld. India currently has more FDA approved manufacturing facilities than any other countryoutside the US. Globally there are only 2 approved biosimilar monoclonal antibodies withReditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian genericmanufacturer) being one of them. As a result, India and its biosimilar manufacturers can beregarded as the front runners in the global biosimilar antibody market race”.Key Aspects Analyzed in this Report: Understanding the strengths, weaknesses, opportunities and challenges in the Indian monoclonal antibodies market Understanding the technological considerations and regulatory factors in the Indian monoclonal antibodies market Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act Understanding the key regulations for registering, manufacturing and importing monoclonal antibodies in India
  • 2. Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not Estimating the patent expiries of various monoclonal antibodies in India, US and Europe Comprehensive situation analysis of the Indian monoclonal antibodies market Analyzing current and future sales of monoclonal antibodies in India Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India Analyzing the global and Indian monoclonal antibodies market by Indication Evaluation of the top selling monoclonal antibodies Key biosimilar antibody development programmes in India and abroadTable of Contents1 Market Definitions & Methodology2 Executive Summary3 Therapeutic Antibodies Market in India 3.1 Industry Analysis 3.1.1 Strengths 3.1.2 Weaknesses 3.1.3 Opportunities 3.1.4 Threats 3.2 Technological & Regulatory Assessment 3.2.1 Technological Assessment 3.2.2 Regulatory Assessment
  • 3. 3.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India 3.4 Market Analysis 3.4.1 Current & Future Sales Trends 3.4.2 Sales Breakup by Molecule 3.4.3 Sales by Indication 3.5 Evaluation of Top Monoclonal Antibodies 3.5.1.1 Avastin 3.5.1.2 Herceptin 3.5.1.3 Rituxan/Mabthera 3.5.1.4 Remicade 3.5.1.5 Humira 3.6 Biosimilar Case Studies 3.6.1 Reditux 3.6.2 Grafeel 3.7 Key Indian & Foreign Biosimilar Antibody Development ProgrammesTo buy the complete report or to get a free sample, please contact: IMARC Group Asia Email: apac@imarcgroup.com Phone: +91-120-415-5099 IMARC Group North America Email: america@imarcgroup.com Phone: +1-631-791-1145
  • 4. IMARC Group Europe, Middle East & AfricaEmail:ema@imarcgroup.comPhone: +44-702-409-7331To know more please visit: http://www.imarcgroup.com/

×